Photo courtesy of ASCO/Todd Buchanan 2016. “The Bean” or Cloud Gate with a little ASCO color, highlighting the 2016 ASCO Annual Meeting, which took place in Chicago, June 3-7.

Lenalidomide maintenance after transplant improves OS in MM



ASCO_2016_Photo by (c) ASCOTodd Buchanan.jpg
McCormick Place, site of
the ASCO Annual Meeting
© ASCO/Todd Buchanan

Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT) should be considered the standard of care in newly diagnosed multiple myeloma (MM) patients, according to a meta-analysis presented at the 2016 ASCO Annual Meeting.... [Read Article]

Most CML patients who stop nilotinib stay in remission



ASCO_2016_Photo by c ASCOMatt Herp 2016.jpg
ASCO Annual Meeting 2016
© ASCO/Matt Herp

Nearly 60% of chronic myeloid leukemia (CML) patients who switch to nilotinib from imatinib maintain treatment-free remission for 48 weeks after stopping treatment, according to a new study, ENESTop, presented at the 2016 ASCO Annual Meeting.Treatment-free remission... [Read Article]

Increased lymphoma risk in patients with PIDD



ASCO_2016_Poster session_Photo by (c) ASCOZach Boyden-Holmes.jpg
Poster session at ASCO 2016
© ASCO/Zach Boyden-Holmes

Investigators have found an increased risk in cancer incidence for patients with primary immunodeficiency diseases (PIDD), and in particular, a significant increase in lymphoma cases. Investigators reviewed records of patients registered in the United States Immune Deficiency... [Read Article]

Tandem ASCT for neuroblastoma comes with caveat



stem_cells_for_transplant_Chad_McNeeley_220.jpg
Stem cells for transplant
Photo by Chad McNeeley

A phase 3 study of tandem autologous stem cell transplant (ASCT) for children with high-risk neuroblastoma has shown that tandem transplant as consolidation significantly improved event-free survival (EFS). Nevertheless, the improvement comes “with an important caveat,” according to Julie R. Park, MD, “that this is in children... [Read Article]

Venetoclax + LDAC has potential in older AML patients



ASCO_2016_Photo by (c) ASCOTodd Buchanan.jpg
Stairway at McCormick Place,
site of ASCO Annual Meeting
© ASCO/Todd Buchanan

Investigators are pursuing the combination of the selective BCL-2 inhibitor venetoclax plus low-dose cytarabine (LDAC) in older, treatment-naïve patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. These patients have few treatment... [Read Article]

Rituximab plus chemo in kids with B-NHL could be practice changing



ASCO_2016_Photo by c ASCOMatt Herp 2016.jpg
ASCO Annual Meeting 2016
© ASCO/Matt Herp

The first interim analysis of rituximab plus chemotherapy in children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and acute leukemia has yielded results that “will change our clinical practice,” according to Veronique Minard-Colin, MD, PhD, one of... [Read Article]

‘Unprecedented’ efficacy for daratumumab in rel/ref MM



Palumbo_Antonio_ASCO 2016 plenary.jpg
Antonio Palumbo, MD

The addition of the monoclonal antibody daratumumab to bortezomib and dexamethasone, the current standard of care for relapsed/refractory multiple myeloma (MM), has achieved progression-free survival that is “unprecedented in randomized studies that compared novel treatment” for this disease, according to Antonio Palumbo, MD, lead author of the phase... [Read Article]

Hispanic, black AYA more likely to die of their cancer



ASCO2016_posters-220.jpg
Poster session at ASCO 2016
© ASCO/Zach Boyden-Holmes

Hispanic white and non-Hispanic black adolescents and young adults (AYA) are more likely to die of their disease than the same-aged white patients, according to a study presented at the 2016 ASCO Annual Meeting. If the chance of a young-adult white patient dying within 2 years... [Read Article]

Upfront ASCT still preferred for young MM patients



HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg
Transplant preparation
Photo by Chad McNeeley

An interim analysis of a large, phase 3 study has confirmed that upfront autologous stem cell transplantation (ASCT) is still the preferred treatment for newly diagnosed, young multiple myeloma (MM) patients, even in the age of novel agents such as bortezomib. Investigators compared 4 cycles of bortezomib-melphalan-prednisone (VMP)... [Read Article]